Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
-
Clin. Gastroenterol. Hepatol. · Feb 2006
Randomized Controlled TrialSafety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.
The safety of selective cyclooxygenase-2 inhibitors in patients with ulcerative colitis in remission is unknown. ⋯ Therapy with celecoxib for up to 14 days did not have a greater relapse rate than placebo in patients with ulcerative colitis in remission who had a present or past history of nonspecific arthritis, arthralgia, or other condition amenable to nonsteroidal anti-inflammatory drug therapy.